Scientists at the University of California, San Francisco demonstrated that CRISPR activation technology can upregulate the functional SCN2A gene copy in mice with haploinsufficiency, a condition causing neurodevelopmental disorders including seizures and autism symptoms. The approach restored synapse maturation and normalized brain signaling, offering therapeutic promise even in juvenile subjects. The study, published in Nature, suggests potential for CRISPRa-based interventions beyond early developmental windows in genetic neurological diseases.